BioVentrix announces the 1st Revivent TC(TM) TransCatheter Ventricular Enhancement procedure for Ischemic Cardiomyopathy treatment at the University Heart Center Zurich in Switzerland

SAN RAMON, Calif., and ZURICH, Sept. 18, 2017 -- (Healthcare Sales & Marketing Network) -- BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced the first clinical use of its closed-ch... Devices, Interventional, Cardiology BioVentrix, Revivent TC, TransCatheter, Ventricular Enhancement
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news